HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VPM1002 recombinant BCG vaccine

use of the VPM1002 vaccine for reducing COVID-19 severity add COVID-19

Also Known As:

BCG vaccine VPM1002; VPM1002; VPM1002 vaccine

Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Bacterial Vaccines: 529
      - Tuberculosis Vaccines: 243
        BCG Vaccine: 1485
        VPM1002 recombinant BCG vaccine: 5

Experts

1.	Cotton, Mark F: 2 articles (10/2022 - 01/2017)
2.	Grode, Leander: 2 articles (10/2022 - 01/2017)
3.	Gutschmidt, Andrea: 2 articles (10/2022 - 01/2017)
4.	Hesseling, Anneke C: 2 articles (10/2022 - 01/2017)
5.	Johnstone, Hilary: 2 articles (10/2022 - 01/2017)
6.	Walzl, Gerhard: 2 articles (10/2022 - 01/2017)
7.	Abraham, Maria: 1 article (10/2022)
8.	Allies, Devon L: 1 article (10/2022)
9.	Bhikha, Sutika: 1 article (10/2022)
10.	Brückner, Sina: 1 article (10/2022)

Related Diseases

1.	Respiratory Tract Infections (Respiratory Tract Infection) 01/01/2023 - "This study evaluates the safety and efficacy of VPM1002 (a genetically modified BCG) as prophylaxis against severe respiratory tract infections including coronavirus disease 2019 (COVID-19) in an elderly population. " 01/01/2023 - "VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study."
2.	COVID-19 01/01/2023 - "This study evaluates the safety and efficacy of VPM1002 (a genetically modified BCG) as prophylaxis against severe respiratory tract infections including coronavirus disease 2019 (COVID-19) in an elderly population. " 01/01/2023 - "The incidence of self-reported fever was lower in the VPM1002 group (odds ratio, 0.46 [95% confidence interval, .28-.74]; P = .001), and consistent trends to fewer hospitalization and ICU admissions due to COVID-19 were observed after VPM1002 vaccination. " 01/01/2023 - "VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study."
3.	Tuberculosis (Tuberculoses) 01/01/2017 - "Newly developed vaccine VPM1002 confers paradigm swing in the prophylactic treatment of tuberculosis (TB). " 01/01/2017 - "VPM1002, a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine previously shown to be safe and immunogenic in adults, was evaluated for safety in its intended target population, namely, newborn infants in a region with high prevalence of tuberculosis. "
4.	Abscess 01/01/2017 - "The incidence of abscess formation was lower for VPM1002 than for BCG. " 10/01/2022 - "Incidence of severe injection site reactions was lower with VPM1002 than BCG: scarring occurred in 65 (21%) participants in the VPM1002 group versus 77 (74%) participants in the BCG group (p<0·0001); ulceration occurred in one (<1%) versus 15 (14%; p<0·0001); and abscess formation occurred in five (2%) versus 23 (22%; p<0·0001). "
5.	Drug-Related Side Effects and Adverse Reactions 10/01/2022 - "The primary outcome was non-inferiority (margin 15%) of VPM1002 to BCG vaccine in terms of incidence of grade 3-4 adverse drug reactions or ipsilateral or generalised lymphadenopathy of 10 mm or greater in diameter by 12 months. "

Related Drugs and Biologics

1.	Vaccines
2.	BCG Vaccine